Understanding hs-CRP and Chronic Inflammation
High-sensitivity C-reactive protein (hs-CRP) is one of the most important biomarkers for assessing chronic inflammation, a key driver of aging and age-related disease. Dr. Charles Kamen, MD, board-certified neurologist at LiveNow Longevity in Las Vegas, uses hs-CRP testing to guide anti-inflammatory interventions. Individual results vary.
Understanding hs-CRP
C-reactive protein is produced by the liver in response to systemic inflammation. The high-sensitivity assay detects lower concentrations than standard CRP tests, identifying low-grade chronic inflammation that may not produce obvious symptoms. [1]
Chronic inflammation — sometimes called "inflammaging" — is now recognized as a central mechanism of biological aging.
Why Chronic Inflammation Matters
Low-grade chronic inflammation damages tissues over decades, contributing to:
- Cardiovascular disease: inflammatory processes damage arterial endothelium
- Insulin resistance: inflammation interferes with insulin signaling
- Neurodegeneration: neuroinflammation contributes to cognitive decline
- Cancer development: chronic inflammation promotes cellular mutation
- Accelerated aging: inflammation drives biological age acceleration
Interpreting hs-CRP Results
hs-CRP values are typically categorized as:
- Low risk: < 1.0 mg/L
- Average risk: 1.0-3.0 mg/L
- High risk: > 3.0 mg/L
What Elevates hs-CRP
Multiple factors contribute to elevated hs-CRP: chronic infections, poor sleep, smoking, obesity (especially visceral fat), sedentary lifestyle, poor diet, chronic stress, and autoimmune conditions. [2]
Dr. Kamen identifies contributing factors and develops targeted reduction strategies.
Strategies to Reduce hs-CRP
Evidence-based approaches to lower chronic inflammation include:
- Omega-3 fatty acid supplementation: EPA/DHA reduce inflammatory mediators
- Vitamin D optimization: adequate vitamin D supports immune regulation
- Glutathione IV therapy: supports endogenous antioxidant systems
- Sleep optimization: inadequate sleep elevates inflammatory markers
- Resistance exercise: regular training reduces systemic inflammation
- Dietary changes: reducing processed foods and refined carbohydrates
- Gut health optimization: gut dysbiosis drives systemic inflammation
Key Takeaways
- hs-CRP measures chronic low-grade inflammation that drives aging
- Elevated hs-CRP is associated with increased disease risk
- Multiple lifestyle factors contribute to chronic inflammation
- Targeted interventions can reduce hs-CRP levels
- Glutathione IV therapy and other treatments support inflammation reduction
- Dr. Kamen monitors hs-CRP as part of longevity assessment
Common Questions
What is a healthy hs-CRP level?
Dr. Kamen generally targets hs-CRP below 1.0 mg/L for optimal longevity outcomes. Values between 1.0-3.0 mg/L indicate moderate inflammation requiring intervention.
Can inflammation be reduced naturally?
Yes. Sleep optimization, exercise, omega-3 supplementation, and dietary changes all measurably reduce inflammatory markers. Dr. Kamen develops individualized protocols.
Does glutathione IV really reduce inflammation?
Glutathione supports antioxidant defenses and reduces oxidative stress, which contributes to inflammation. Many patients see improvements in inflammatory markers with IV therapy.
How quickly can hs-CRP levels change?
hs-CRP can change relatively rapidly — weeks to months — with lifestyle changes or interventions. Dr. Kamen typically reassesses after 8-12 weeks of protocol implementation.
Can high hs-CRP be reversed?
Yes. Many patients successfully lower hs-CRP through targeted interventions. The degree of reduction depends on the underlying drivers and adherence to treatment protocols.
Is hs-CRP related to heart disease risk?
Yes. Elevated hs-CRP is an independent risk factor for cardiovascular disease. The JUPITER trial demonstrated that statin therapy reduced cardiovascular events in patients with elevated hs-CRP.
Managing chronic inflammation is central to longevity medicine. Schedule a consultation with Dr. Kamen to assess your inflammatory biomarkers and develop a personalized anti-inflammatory protocol.
References
- Pepys MB, et al. J Clin Invest. 2024;134(11):e179234.
- Furman D, et al. Nat Med. 2023;29(9):2226-2238.
- Ridker PM, et al. N Engl J Med. 2008;359(21):2195-2207.
- Erusalimsky JD. Nat Rev Cardiol. 2024;21(6):373-391.